Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 311-317 , August 2007

Antenatal magnesium sulphate neuroprotection in the preterm infant

  • Stéphane Marret

      Affiliations

    • Department of Neonatal Medicine, University Hospital, 1, rue de Germont, 76031 Rouen Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 2 32 88 80 97; fax: +33 2 32 88 86 33.
    • ,
  • Lex W. Doyle

      Affiliations

    • The Royal Women's Hospital, University of Melbourne, Melbourne, Australia
    • Murdoch Children's Research Institute, Melbourne, Australia
    • ,
  • Caroline A. Crowther

      Affiliations

    • Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia
    • ,
  • Philippa Middleton

      Affiliations

    • Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia

References 

  1. Doyle LW The Victorian Infant Collaborative Study Group. Evaluation of neonatal intensive care for extremely low birth weight infants in Victoria over two decades: II. Efficiency. Pediatrics. Mar 2004;113:510–514
  2. Marlow N, Wolke D, Bracewell MA, Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med. 2005;352:9–19
  3. Ancel PY, Livinec F, Larroque B, et al. Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE cohort study. Pediatrics. 2006;117:828–835
  4. Anderson PJ, Doyle LW The Victorian Infant Collaborative Study Group. Neurobehavioral outcomes of school-age children born extremely low birth weight or very preterm in the 1990s. JAMA. 2003;289:3264–3272
  5. Anderson PJ, Doyle LW For the Victorian Infant Collaborative Study Group. Executive functioning in school-aged children who were born very preterm or with extremely low birth weight in the 1990s. Pediatrics. 2004;114:50–57
  6. Botting N, Powls A, Cooke RW, Marlow N. Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years. J Child Psychol Psychiatry. 1997;38:931–941
  7. O'Callaghan MJ, Harvey JM. Biological predictors and co-morbidity of attention deficit and hyperactivity disorder in extremely low birthweight infants at school. J Paediatr Child Health. 1997;33:491–496
  8. Marret S, Marpeau L. Grand prematurity, risk of neuropsychic handicaps and neuroprotection, J Gynecol Obstet Biol Reprod (Paris). 2000;29:373–384
  9. Inder TE, Wells SJ, Mogridge NB, Spencer C, Volpe JJ. Defining the nature of the cerebral abnormalities in the premature infant: a qualitative magnetic resonance imaging study. J Pediatr. 2003;143:171–179
  10. Larroque B, Marret S, Ancel PY, et al. White matter damage and intraventricular hemorrhage in very preterm infants: the EPIPAGE study. J Pediatr. 2003;143:477–483
  11. Caddell JL, Graziani LJ, Wiswell TE, Hsieh HC, Mansmann HC. The possible role of magnesium in protection of premature infants from neurological syndromes and visual impairments and a review of survival of magnesium-exposed premature infants. Magnes Res. 1999;12:201–216
  12. Nelson KB. Can we prevent cerebral palsy?. N Engl J Med. 2003;349:1765–1769
  13. Actobat Study Group . Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease. Lancet. 1995;345:877–882
  14. Crowther CA, Hiller JE, Haslam RR, Robinson JS. Australian collaborative trial of antenatal thyrotropin-releasing hormone: adverse effects at 12-month follow-up. ACTOBAT Study Group. Pediatrics. 1997;99:311–317
  15. Ment LR, Oh W, Ehrenkranz RA, et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomised trial. Pediatrics. 1994;93:543–550
  16. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight Infants. N Engl J Med. 2001;344:1966–1972
  17. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. The Cochrane Database of Systematic Reviews. 2002;(4):Art. No.: CD001060
  18. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet. 2002;359:1877–1890
  19. Mildvan AS. Role of magnesium and other divalent cations in ATP-utilizing enzymes. Magnesium. 1987;6:28–33
  20. McIntosh TK, Vink R, Yamakami I, Faden AI. Magnesium protects against neurological deficit after brain injury. Brain Res. Mar 20 1989;482:252–260
  21. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoria-Papadopoulos M. Protective effect of MgSO4 infusion on NMDA receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain Res. 1994;644:144–149
  22. Shogi T, Miyamoto A, Ishiguro S, Nishio A. Enhanced release of IL-1beta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-Mg(2+) medium. Magnes Res. 2003;16:111–119
  23. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984;307:462–465[8]
  24. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003;3:9–20
  25. Schiff SJ, Somjen GG. Hyperexcitability following moderate hypoxia in hippocampal tissue slices. Brain Res. 1985;337:337–340
  26. Maier JA, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta. 2004;1689:13–21
  27. Rantone TH, Gronlund JU, Jalonen JO, et al. Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Clin Physiol Funct Imaging. 2002;22:13–17
  28. MacDonald RL, Curry DJ, Aihara Y, Zhang ZD, Jahromi BS, Yassari R. Magnesium and experimental vasospasm. J Neurosurg. 2004;100:106–110
  29. Hallak M, Cotton DB. Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: assessment of amniotic fluid, blood, and brain concentrations. Am J Obstet Gynecol. 1993;169:427–431
  30. Levene M, Blennow M, Whitelaw A, Hanko E, Fellman V, Hartley R. Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. Arch Dis Child Fetal Neonatal Ed. 1995;73:F174–F177
  31. Canton R, Manzanares J, Alvarez E, Zaragoza F. In vitro and in vivo antiaggregant effects of magnesium halogenates. Thromb Haemost. 1987;58:957–959
  32. Sipes SL, Chestnut DH, Vincent RD, DeBruyn CS, Bleuer SA, Chatterjee P. Which vasopressor should be used to treat hypotension during magnesium sulfate infusion and epidural anesthesia?. Anesthesiology. 1992;77:101–108
  33. Keeley MM, Wade RV, Laurent SL, Hamann VD. Alterations in maternal-fetal Doppler flow velocity waveforms in preterm labor patients undergoing magnesium sulfate tocolysis. Obstet Gynecol. 1993;81:191–194
  34. Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology. 1987;67:806–808
  35. Krendal DA. Hypermagnesaemia and neuromuscular transmission. Semin Neurol. 1990;10:42–45
  36. McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-d-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci Lett. 1990;109:234–238
  37. Marret S, Gressens P, Gadisseux JF, Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev Med Child Neurol. 1995;37:473–484
  38. Galvin KA, Oorschot DE. Postinjury magnesium sulfate treatment is not markedly neuroprotective for striatal medium spiny neurons after perinatal hypoxia/ischemia in the rat. Pediatr Res. 1998;44:740–745
  39. Sameshima H, Ikenoue T. Long-term magnesium sulfate treatment as protection against hypoxic/ischemic brain injury in seven-day-old rats. Am J Obstet Gynecol. 2001;184:185–190
  40. Turkyilmaz C, Turkyilmaz Z, Atalay Y, Soylemezoglu F, Celasun B. Magnesium pre-treatment reduces neuronal apoptosis in newborn rats in hypoxia–ischemia. Brain Res. 2002;955:133–137
  41. Mami AG, Ballesteros J, Mishra OP, Delivoria-Papadopoulos M. Effects of magnesium sulfate administration during hypoxia on Ca(2+) influx and IP(3) receptor modification in cerebral cortical neuronal nuclei of newborn piglets. Neurochem Res. 2006;31:63–70
  42. Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol. 1995;54:358–370
  43. Thordstein M, Bagenholm R, Thiringer K, Kjellmer I. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr Res. 1993;34:23–26
  44. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics. 1995;95:263–269
  45. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA. 1996;276:1805–1810
  46. Paneth N, Jetton J, Pinto-Martin J, Susser M. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The neonatal brain hemorrhage study analysis group. Pediatrics. 1997;99:E1
  47. O'Shea TM, Klinepeter KL, Dillard RG. Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol. 1998;147:362–369
  48. Boyle CA, Yeargin-Allsopp M, Schendel DE, Holmgreen P, Oakley GP. Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less than 1,750 grams. Am J Epidemiol. 2000;152:120–124
  49. Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol. 2000;183:717–725
  50. Mittendorf R, Dambrosia J, Pryde PG, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002;186:1111–1118
  51. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet. 1997;350:1517–1518[22]
  52. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomised controlled trial. JAMA. 2003;290:2669–2676
  53. Magpie Trial Follow-up Study Collaborative Group . The Magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. Br J Obstet Gynaecol. 2007;114:289–299
  54. Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. Br J Obstet Gynaecol. 2007;114:310–318
  55. Stanley FJ. Using cerebral palsy data in the evaluation of neonatal intensive care: a warning. Dev Med Child Neurol. 1982;24:93–94
  56. Ford GW, Kitchen WH, Doyle LW, Rickards AL, Kelly E. Changing diagnosis of cerebral palsy in very low birthweight children. Am J Perinatol. 1990;7:178–181

PII: S1744-165X(07)00055-8

doi: 10.1016/j.siny.2007.04.001

Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 311-317 , August 2007

Article Tools